![OHSU News on X: "COVID-19 booster shot timing. Two of the widely available COVID-19 vaccines, from Moderna and from Pfizer, are designed to be most effective after two doses. But what if OHSU News on X: "COVID-19 booster shot timing. Two of the widely available COVID-19 vaccines, from Moderna and from Pfizer, are designed to be most effective after two doses. But what if](https://pbs.twimg.com/media/Ex5LuSGWEAIP7SJ.jpg)
OHSU News on X: "COVID-19 booster shot timing. Two of the widely available COVID-19 vaccines, from Moderna and from Pfizer, are designed to be most effective after two doses. But what if
![COVID-19 Vaccine Second-Dose Completion and Interval Between First and Second Doses Among Vaccinated Persons — United States, December 14, 2020−February 14, 2021 | MMWR COVID-19 Vaccine Second-Dose Completion and Interval Between First and Second Doses Among Vaccinated Persons — United States, December 14, 2020−February 14, 2021 | MMWR](https://www.cdc.gov/mmwr/volumes/70/wr/social-media/mm7011e2_COVID19VaccineDose2_IMAGE_12Mar21_v4_1200x627.jpg?_=39294)
COVID-19 Vaccine Second-Dose Completion and Interval Between First and Second Doses Among Vaccinated Persons — United States, December 14, 2020−February 14, 2021 | MMWR
![ATAGI Statement on the Omicron variant and the timing of COVID-19 booster vaccination | Australian Government Department of Health and Aged Care ATAGI Statement on the Omicron variant and the timing of COVID-19 booster vaccination | Australian Government Department of Health and Aged Care](https://www.health.gov.au/sites/default/files/styles/h_content_max_width_no_upscale/public/images/news/2021/12/atagi-statement-on-the-omicron-variant-and-the-timing-of-covid-19-booster-vaccination.jpeg?itok=GjQQzYCC)
ATAGI Statement on the Omicron variant and the timing of COVID-19 booster vaccination | Australian Government Department of Health and Aged Care
![Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR](https://www.cdc.gov/mmwr/volumes/71/wr/social-media/mm7148e1-BivalentBooster_IMAGE_22NOV2022_1200x675.jpg?_=65732)